Inhibrx Biosciences (INBX) Projected to Post Earnings on Wednesday

Posted by Geri Gentry on May 6th, 2026

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Inhibrx Biosciences to post earnings of ($1.6750) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last posted its earnings results on Thursday, March 19th. The company reported ($2.11) EPS for the quarter, missing analysts’ consensus estimates of ($2.08) by ($0.03). On average, analysts expect Inhibrx Biosciences to post $-11 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Inhibrx Biosciences Price Performance

NASDAQ:INBX opened at $128.12 on Wednesday. Inhibrx Biosciences has a 52 week low of $10.84 and a 52 week high of $155.29. The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 12.58. The company has a market capitalization of $1.87 billion, a P/E ratio of -14.17 and a beta of 3.88. The stock’s fifty day moving average is $80.33 and its two-hundred day moving average is $77.63.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Stifel Nicolaus assumed coverage on Inhibrx Biosciences in a research report on Wednesday, April 8th. They issued a “buy” rating and a $150.00 target price on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Inhibrx Biosciences in a research report on Thursday, January 22nd. Lifesci Capital upgraded Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Wall Street Zen upgraded Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research upgraded Inhibrx Biosciences to a “hold” rating in a research report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Inhibrx Biosciences presently has a consensus rating of “Hold” and an average target price of $150.00.

View Our Latest Report on INBX

Institutional Investors Weigh In On Inhibrx Biosciences

Several institutional investors and hedge funds have recently modified their holdings of INBX. Strs Ohio purchased a new stake in shares of Inhibrx Biosciences in the 1st quarter valued at $27,000. Russell Investments Group Ltd. raised its holdings in shares of Inhibrx Biosciences by 11.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 29,993 shares of the company’s stock valued at $428,000 after buying an additional 2,963 shares during the period. Invesco Ltd. purchased a new stake in shares of Inhibrx Biosciences in the 2nd quarter valued at $193,000. Bank of America Corp DE raised its holdings in shares of Inhibrx Biosciences by 19.2% in the 2nd quarter. Bank of America Corp DE now owns 9,130 shares of the company’s stock valued at $130,000 after buying an additional 1,469 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Inhibrx Biosciences in the 2nd quarter valued at $235,000. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Inhibrx Biosciences Company Profile

(Get Free Report)

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.